GlaxoSmithKline’s darapladib team finds hope in a PhIII bomb

John Carroll

No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backward to highlight any positive sign of efficacy, no matter how weak the signal. And GlaxoSmithKline's at the American College of Cardiology meeting over the weekend was in full spin mode with their heart drug .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS